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Graphical Abstract 
 
 
Abstract 
The high-performance liquid chromatography (HPLC) method employing stationary 
phases immobilized with plasma proteins was used for this study to investigate the structural 
properties governing drug-plasma protein binding. A set of 65 compounds with a broad range 
of structural diversity (in terms of volume, hydrogen-bonding, polarity and electrostatic 
force) were selected for this purpose. The Abraham linear free energy relationship (LFER) 
analyses of the retention factors on the immobilized HSA (human serum albumin) and AGP 
(α1-acid glycoprotein) stationary phases showed that McGowan’s characteristic molecular 
volume (V), dipolarity/polarizability (S) and hydrogen bond basicity (B) are the three 
significant molecular descriptors of solutes determining the interaction with immobilized 
plasma proteins, whereas excess molar refraction (E) is less important and hydrogen bond 
acidity (A) is not of statistical significance in both systems, for electrically neutral 
compounds. It was shown that ionised acids, as carboxylate anions, bind very strongly to the 
immobilised HSA stationary phase and that ionised bases, as cations bind strongly to the 
AGP stationary phase. This is the first time that the effect of ionised species on plasma 
protein binding has been determined quantitatively; the increased binding of acids to HSA is 
due almost entirely to acids in their ionised form. 
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1. Introduction 
The binding of drugs to plasma proteins is an important process that determines the 
activity and pharmacokinetics of many drugs in the body. After being distributed around the 
circulating system, drugs bind to plasma proteins in varying degrees. In general, such binding 
is reversible, and an equilibrium exists between bound and free molecular forms. In most 
cases, only the free drug molecules are able to cross membrane barriers, be distributed to 
tissues and then exert therapeutic effects [1,2]. Drug-plasma protein binding acts as a 
reservoir for free drug concentration and prolongs the duration of drug action. Therefore 
drug-plasma protein binding is considered as an important property and needs to be 
characterized in the early stage of drug discovery [3]. 
In plasma, two major proteins, human serum albumin (HSA) and α1-acid glycoprotein 
(AGP) are present in relatively high quantities. They are able to bind a variety of drugs with 
considerable affinity [4]. It is found that HSA with the highest concentration (5-7.5×10-4 
mol/L) in plasma has two major binding sites and can bind acidic drugs with high association 
constants. AGP is an acidic protein with a lower concentration (0.9-2.2×10-5 mol/L). It 
exhibits a preference for binding basic and neutral drugs. Lipoproteins which are 
macromolecular complexes of lipid and proteins also play a role to a lesser degree [5].  
There are different techniques to determine drug-plasma protein binding in vitro. Among 
these techniques, equilibrium dialysis, ultra-filtration and ultra-centrifugation have been most 
widely used. However, these methods show a number of limitations such as a very low 
throughput and poor reproducibility [6]. In comparison to these conventional methods, the 
HPLC method that employs stationary phases immobilized with plasma proteins appears an 
interesting approach because of the speed of analysis and automation capability [7,8]. In this 
method, drugs with high affinities interact strongly with the immobilized protein and are 
eluted later than drugs with no or less affinities. The affinity is expressed by the retention 
factor k, which is calculated through Eq. 1 
k = (tr – t0)/t0       Eq.1 
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where tr and t0 are the retention times of the solute and of an unretained compound, 
respectively.  
A number of studies have been carried out to investigate drug-plasma protein interaction 
by using special classes of drugs [9-13]. In order to understand comprehensively the 
mechanisms of drug-plasma protein interaction, we selected for this study a set of drugs with 
a broad range of structural diversity (in terms of volume, hydrogen-bonding, polarity and 
electrostatic force). The interaction between these drugs and immobilized plasma proteins 
(HSA and AGP) was measured using the HPLC method. By employing a linear free-energy 
relationship (LFER) model [14-16], we aim to establish quantitative structure-drug-plasma 
protein binding relationships and to unravel the structural parameters governing the 
interaction mechanisms, which are very important for drug design. These quantitative 
relationships can be used to estimate protein binding of drugs in the early stages of drug 
discovery, and so will be of considerable use and importance. 
2. Materials and methods 
2.1. Solutes and reagents 
All compounds were obtained from commercial sources (Sigma-Aldrich, Gillingham, UK) 
and in the highest available purity. Distilled water and HPLC grade isopropanol (Fisher 
Scientific, Loughborough UK) were used throughout. 
2.2. Measurement of retention factors 
The retention factors were measured with a Waters 2695 Alliance HPLC system with 
Waters 996 PDA detector (Waters Millipore, Milford USA). Immobilized CHIRALPAK® 
HSA (100×4 mm, 5 μm) and AGP (100×4.0 mm, 5 μm) HPLC columns were purchased from 
DAICEL Chemical Industries, Ltd (Illkirch Cedex, France. The mobile phase was composed 
of a 0.02 M phosphate buffer pH 7.0, and isopropanol (IPA) in proportions of 15% (v/v). The 
retention times of the solute tr and a non-retained compound (IPA) t0 were measured at room 
temperature by a 996 PDA detector. The solutions to be injected (10-4 to 10-5 M) were 
prepared by dissolving the solutes in the mobile phase; the injection volume was 10 µL. The 
measurements were carried out at a flow rate of 0.8 ml/min for all compounds. The isocratic 
retention factor k was calculated by Eq. 1. All log k values were the average of three 
measurements.  
2.3 Linear free-energy relationship (LFER) model 
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LFER method was used in this study to establish the quantitative structure-drug-plasma 
protein binding relationships. LFER method was firstly applied to the properties of neutral 
molecules [17] and subsequently extended to include ions and ionic species by Abraham and 
Acree [14-16]. The general equation developed by Abraham and Acree is stated as: 
SP = c + eE + sS + aA + bB + vV + j+J+ + j−J−     Eq. 2 
The dependent variable SP represents the logarithm of an equilibrium coefficient for a series 
of solutes in a given system, including partition coefficients, rate coefficients, and in the 
present work logarithm of retention factors (log k) of the solutes investigated (Table 1). The 
independent variables are the physicochemical properties or descriptors of the solutes as 
follows. E is the excess molar refraction in units of (cm3/mol)/10, S is the combined 
dipolarity/polarizability, A and B are the overall solute hydrogen bond acidity and basicity, 
and V is McGowan’s characteristic molecular volume in units of (cm3/mol)/100; J+ and J- 
are the additional descriptors that are specific to ionic species. Note that J+ = 0 for anions, J− 
= 0 for cations, and both J+ and J− = 0 for neutral molecules. In the latter case, Eq. 2 reduces 
to an equation for neutral molecules. The compound descriptors for neutral molecules are 
obtained from a variety of experimental processes, as explained in a number of reviews 
[18,19], and Abraham and Acree have reviewed the methods used to obtain descriptors for 
ions and ionic species [20]. The coefficients (c, e, s, a, b, v, j+ and j-) in Eq. 2 can be obtained 
by a multiple linear regression (MLR) of values of SP (log k in this study) in a given system 
against the known solute descriptors, and used to characterize the system of interest. 
It is important to note that for neutral compounds, Eq. 2 with j+ and j- = 0, each term in 
the equation corresponds to a particular solute-system interaction. Thus the aA term refers to 
interaction between a neutral solute that is a hydrogen bond acid and the system acting as a 
hydrogen bond base. However, this simple interpretation does not apply to ionised species. In 
the equation for neutrals and ions, Eq. 2, the coefficients c, s, a, b and v are fixed as those for 
the corresponding equation just for neutrals (when the terms in j+J+ + j−J− are both zero). 
This means that when the descriptors for ions and ionic species are determined they are 
constrained by the necessity that c, s, a, b and v are fixed. Then the descriptors for ionic 
species are simply those that reproduce the experimental values, and do not have the 
theoretical significance that the neutral descriptors have. The j+J+ and  j−J− terms in Eq. 2 
act as ‘correction’ terms for the effect of electric charge on the other equation terms, and so 
only the total effect on SP can be deduced.  
3. Results and discussion 
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In this study, a set of 65 compounds with a broad structural diversity (in terms of E, S, A, 
B, V, J+ and J-) were selected. The solutes consist of neutrals, acidic and basic compounds 
which are present as neutral or ionic (cationic or anionic) at the experimental condition of pH 
7, which is as close as possible to the physiologic pH and compatible with the stability of the 
stationary phase (pH no higher than 7.0). Their retention factors log k were determined using 
immobilized HSA and AGP HPLC columns at the isocratic mobile phase condition. 15% 
(v/v) of IPA was used as the organic modifier to allow the elution of most of the solutes in a 
reasonable time. The two columns were stable during the study period. The stability of HSA 
stationary phase was controlled by injecting 4 compounds (17-hydroxyprogesterone, 
salicylic acid, warfarin and penbutolol) throughout the study, whereas the compounds for 
stability control of AGP column were 17-hydroxyprogesterone, mefenamic acid, warfarin 
and penbutolol.  
The log k values and other physicochemical parameters including dissociation constant 
pKa, n-octanol/water partition coefficient (log Poct), n-octanol/water distribution coefficient at 
pH 7 (log D7.0), as well as the values of the solute descriptors are shown in Table 1. 
(Table 1 here) 
From Table 1, we can see the large log k values of the acidic compounds on the 
immobilized HSA HPLC column (log kHSA). At the experimental condition of pH 7, the 
acidic compounds (35-46 in Table 1) are negatively charged. This indicates the strong 
interaction of anionic species with HSA stationary phase. Four acidic compounds with high 
lipophilicity (flurbiprofen, ibuprofen, mefenamic acid and 8-phenyloctanoic acid) could not 
be eluted from the HSA column (within 4 hours), implying the contribution of lipophilicity of 
the solute to the binding in addition to their negative charges. In this case, we eluted the 
injected samples by mobile phase with higher ratio of IPA before next injection. On the 
contrary, the acidic compounds showed much weaker retention on the AGP HPLC column. 
All the acidic compounds with log Poct values lower than 3 do not retain in AGP column. The 
four highly lipophilic acids (flurbiprofen, ibuprofen, mefenamic acid and 8-phenyloctanoic 
acid) showed a low degree of retention, indicating that the negative charges of the solutes do 
not favour the interaction with AGP, while lipophilicity plays a role.  
Fig 1 shows the correlations between the values of log D7.0 and log k on the immobilized 
HSA (log kHSA) (1a) and AGP (log kAGP) (1b) stationary phases from this study. From Fig 1a, 
it can be further verified that anions interact much stronger with HSA stationary phase than 
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cations and neutral compounds. Fig 1b shows that the cations have a higher affinity to AGP 
stationary phase than anions in general. The neutral compounds bind least to both proteins. 
Within each set of the solutes, the larger the lipophilicity (expressed by log D7.0), the higher 
the affinity with the proteins, indicating that drug binding to immobilized proteins is 
controlled by both electrostatic forces and lipophilicity. This is in good agreement with drug 
binding data from soluble human plasma proteins in previous studies [22]. 
(Fig 1 here) 
To reveal the structural properties that govern the drug interaction with the immobilized 
HSA and AGP in HPLC system, the multilinear regression (MLR) of log k against the solute 
descriptors yielded the LFER model shown in Eq 3 and Eq 4. 
log kHSA = -0.271(±0.298) + 0.470(±0.276)E - 0.331(±0.190)S - 0.177(±0.197)A - 
1.233(±0.393)B + 1.086(±0.0.350)V - 0.231(±0.229)J+ + 2.024 ((±0.460) J- 
N=61, R2=0.812, SD=0.215, F=33, Press=3.204, Q2=0.756  Eq. 3 
log kAGP = -0.756(±0.315) + 0.428(±0.275)E - 0.354(±0.196)S - 0.156(±0.206)A - 
1.253(±0.397)B + 1.278((±0.361)V - 0.051(±0.230)J+ + 1.562 ((±0.426)J- 
N=58, R2=0.796, SD=0.228, F = 28, Press=4.143, Q2=0.674  Eq. 4 
In these equations, 95% confidence limits are given in parentheses; N is the number of 
compounds; R2 is the squared correlation coefficient; SD is the standard deviation, and F is 
the Fisher’s test. Press and Q2 are the leave-one-out statistics. The values of Q2 are good 
enough to indicate that Eq 3 and Eq 4 are soundly based.   
The coefficients of Eq 3 and Eq 4 showed that for the electrically neutral compounds, 
McGowan’s characteristic molecular volume (V), dipolarity/polarizability (S) and hydrogen 
bond basicity (B) are the three significant molecular descriptors of solutes determining the 
interaction with immobilized plasma proteins, whereas excess molar refraction (E) is less 
important and hydrogen bond acidity (A) is not of statistical significance in both systems.  
For acids and bases in this study, we compared logarithm of the retention factors of neutral 
species and the corresponding anions or cations on the two stationary phases as shown in 
Table 2. For immobilized HSA stationary phase, we use Eq. 3 to calculate log kHSA for the 8 
neutral acidic compounds and 19 basic compounds using descriptors for the neutral species. 
These can then be compared to experimental values of log kHSA of the corresponding anions 
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and cations, measured in this study. Over the 8 acidic compounds, the average difference log 
kHSA (anions) – log kHSA (neutral acids) = 0.80 (±0.03) log units, so that on average the 
retention factor on immobilized HSA column for the anions is 6.3 times that for the neutral 
acidic compounds, further quantitatively verifying the contribution of the electrostatic 
interactions between the anions and the immobilized HSA. It also means that for the 
electrically neutral acids, hydrogen bond acidity (A) is not important for binding with the 
HSA phase. In the case of 19 basic compounds, the average difference log kHSA (cations) - 
log kHSA (neutral base) = - 0.14 (±0.01) log units, meaning that retention factor on HSA 
HPLC column for the protonated base cation is 0.71 times that for the neutral bases. This 
indicates that positive charge of the solute does not greatly favour the interaction with HSA 
stationary phase. Thus, for the first time, we are able to show quantitatively the effect of 
negative or positive charge on binding to HSA.  
Valko et al [7] have used a fast gradient HPLC method to study a variety of compounds on 
an immobilised HSA column. By comparison of log kHSA with calculated values of log 
P(octanol) at pH 7.4 (log D) they concluded that acid anions were strongly bound. However, 
they could not quantify any increased binding due to the negative charge. 
Table 2 here 
In the same way, we use Eq 4 to calculate log kAGP for the neutral species of the acids and 
bases used in this study, and then compared to experimental values of log kAGP of the 
corresponding ionic species of neutral acidic compounds and basic compounds obtained from 
this work on immobilized AGP stationary phase (shown in Table 2). For the 5 acidic 
compounds, the average difference log kAGP (neutral acids) – log kAGP (anions) = 0.31 (±0.05) 
log units, so that on average the retention factor on HPLC AGP stationary phase for the 
neutral acidic compounds is twice that for the anions. This further quantitatively confirms 
that anions do not favour interaction with the AGP stationary phase. For the 19 basic 
compounds, the average difference log kAGP (cation) – log kAGP (neutral base) = 0.32 (±0.02), 
meaning that the retention factor on HPLC AGP stationary phase for the protonated base 
cations is about 2.1 times that for neutral bases. This indicates the importance of the positive 
charge in the drug binding with immobilized AGP phase. 
4 Conclusion 
By using the HPLC method that employs the stationary phases immobilized with plasma 
proteins (HSA and AGP), the drug-plasma protein binding was investigated for a set of 
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compounds with a broad range of structural diversity. The obtained LFER model shows that 
for neutral compounds the structural parameters S, B and V are the prominent factors 
governing drug binding with HPLC stationary phases immobilized with HSA and AGP, 
whereas E is less important and A is not of statistical significance in both systems. For ionic 
compounds, electrostatic interactions play a major role in binding. The ionised acids, as 
anions, show very strong interaction with immobilized HSA stationary phase compared to 
immobilized AGP phase, whereas ionised basic compounds, as cations, interact with 
immobilized AGP phase stronger than the HSA phase. 
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Figures 
Figure 1. Correlations between log D7.0 and log kHSA (1a) as well as log kAGP (1b). Markers: ●, neutral molecules; ■, anions; ○, cations  
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Table 1: Physicochemical parameters of the investigated compounds 
No. Solutes pKaa Charge 
state 
log kHSA
b log kAGP
b 
 
log Poct
a log D7.0
c E S A B V J+ J- 
 Neutrals              
1 Acetaminophen 9.50 neutral -0.35 -0.73 0.51 0.51 1.120 1.63 1.01 0.91 1.1724 0.0000 0.0000 
2 Acetophenone N neutral 0.05 -0.30 1.58 1.58 0.818 1.01 0.00 0.48 1.0139 0.0000 0.0000 
3 Acridine 5.58 neutral 1.22 0.90 3.40 3.38 2.356 1.32 0.00 0.58 1.4133 0.0000 0.0000 
4 Aniline 4.60 neutral -0.21 -0.45 0.90 0.90 0.955 0.96 0.26 0.41 0.8162 0.0000 0.0000 
5 2-Chloroaniline 2.64 neutral 0.31 0.05 1.91 1.91 1.033 0.92 0.25 0.31 0.9386 0.0000 0.0000 
6 N-Ethylaniline 5.12 neutral 0.15 -0.05 2.16 2.15 0.945 0.85 0.17 0.43 1.0980 0.0000 0.0000 
7 Nitrobenzene N neutral 0.33 -0.13 1.85 1.85 0.871 1.11 0.00 0.28 0.8906 0.0000 0.0000 
8 1-Chloro-2-nitrobenzene N neutral 0.75 0.24 2.52 2.52 1.020 1.24 0.00 0.24 1.0130 0.0000 0.0000 
9 1-Fluoro-2,4-dinitrobenzene N neutral 0.26 -0.29 1.47 1.47 1.006 1.69 0.00 0.45 1.0825 0.0000 0.0000 
10 Benzyl alcohol N neutral -0.23 -0.42 1.10 1.10 0.803 0.87 0.39 0.56 0.9160 0.0000 0.0000 
11 4-Chlorobenzylalcohol N neutral 0.28 -0.09 1.96 1.96 0.911 0.96 0.40 0.50 1.0384 0.0000 0.0000 
12 2-Aminobiphenyl 3.84 neutral 0.79 0.72 2.84 2.84 1.600 1.48 0.26 0.41 1.4240 0.0000 0.0000 
13 Carbamazepine N neutral 0.23 0.71 2.19 2.19 2.154 1.90 0.50 1.15 1.8106 0.0000 0.0000 
14 Corticosterone N neutral 0.31 0.18 1.94 1.94 1.860 3.43 0.40 1.63 2.7389 0.0000 0.0000 
15 m-Cresol 10.10 neutral 0.23 -0.11 1.96 1.96 0.822 0.88 0.57 0.34 0.9160 0.0000 0.0000 
16 p-Cresol 10.26 neutral 0.24 -0.15 1.94 1.94 0.820 0.87 0.57 0.31 0.9160 0.0000 0.0000 
17 Estradiol N neutral 1.26 0.74 3.03 3.03 1.800 1.77 0.86 1.10 2.1988 0.0000 0.0000 
18 Estriol N neutral 0.68 -0.03 2.54 2.54 1.970 1.74 1.06 1.63 2.2575 0.0000 0.0000 
19 Hydrocortisone N neutral -0.02 -0.15 1.61 1.61 2.030 3.49 0.71 1.90 2.7976 0.0000 0.0000 
20 Hydrocortisone- 21-acetate N neutral 0.24 0.18 2.19 2.19 1.890 2.88 0.46 2.16 3.0951 0.0000 0.0000 
21 2- Naphthol 9.57 neutral 0.94 0.47 2.70 2.70 1.520 1.08 0.61 0.40 1.1441 0.0000 0.0000 
22 3-Chlorophenol 9.11 neutral 0.71 0.26 2.50 2.50 0.909 1.06 0.69 0.15 0.8975 0.0000 0.0000 
14 
 
23 4-Bromophenol 9.31 neutral 0.82 0.30 2.59 2.59 1.080 1.17 0.67 0.20 0.9501 0.0000 0.0000 
24 4-Chlorophenol 9.40 neutral 0.65 0.17 2.39 2.39 0.915 1.08 0.67 0.20 0.8975 0.0000 0.0000 
25 4-Chloro-3,5-dimethyl 
phenol 
9.70 neutral 1.22 0.82 3.27 3.27 0.980 0.94 0.61 0.26 1.1793 0.0000 0.0000 
26 4-Chloro-2-methylphenol 9.60 neutral 0.92 0.50 2.78 2.78 0.890 0.91 0.63 0.22 1.0384 0.0000 0.0000 
27 3-Nitrophenol 8.40 neutral 0.48 -0.09 2.00 1.98 1.050 1.57 0.79 0.23 0.9493 0.0000 0.0000 
28 Phenylacetonitrile N neutral 0.10 -0.52 1.56 1.56 0.751 1.03 0.00 0.50 1.0120 0.0000 0.0000 
29 Phenytoin 8.33 neutral 0.41 0.25 2.47 2.45 1.713 2.23 0.86 1.00 1.8693 0.0000 0.0000 
30 Prednisolone N neutral 0.02 -0.12 1.62 1.62 2.210 3.10 0.71 1.92 2.7546 0.0000 0.0000 
31 17α-Hydroxyprogesterone N neutral 0.78 0.71 3.17 3.17 1.640 3.35 0.25 1.31 2.6802 0.0000 0.0000 
32 21-Hydroxyprogesterone N neutral 0.81 0.60 3.10 3.10 1.740 3.50 0.14 1.31 2.6802 0.0000 0.0000 
33 Salicylamide 8.37 neutral 0.02 -0.26 1.28 1.26 1.160 1.58 0.61 0.51 1.0315 0.0000 0.0000 
34 Testosterone N neutral 0.78 0.66 3.32 3.32 1.540 2.56 0.32 1.17 2.3827 0.0000 0.0000 
 Acidic compounds              
35 Aspirin 3.48 Anion 0.86  1.13 -2.39 1.000 4.15 0.00 3.28 1.2664 0.0000 2.2560 
36 4-Bromobenzoic Acid 3.97 Anion 1.33  2.86 -0.17 1.150 3.25 0.00 2.60 1.0852 0.0000 2.1480 
37 3-Chlorobenzoic Acid 3.82 Anion 1.04  2.71 -0.47 0.990 3.13 0.00 2.57 1.0326 0.0000 2.0340 
38 4-Chlorobenzoic acid 3.98 Anion 1.07  2.65 -0.37 0.990 3.37 0.00 2.60 1.0326 0.0000 2.1790 
39 Flurbiprofen 3.91 Anion  0.14 3.81 0.72 1.590 4.56 0.07 3.36 1.8174 0.0000 2.5383 
40 Ibuprofen 4.43 Anion  0.04 3.87 1.30 0.880 3.50 0.08 3.31 1.7556 0.0000 2.4188 
41 Mefenamic acid 4.33 Anion  0.63 5.12 2.45 1.800 4.71 0.09 3.14 1.8996 0.0000 2.6427 
42 3-Phenylpropanoic acid 4.25 Anion 1.08  1.89 -0.86 0.900 3.43 0.03 3.02 1.1920 0.0000 2.1879 
43 4-Phenylbutanoic acid 4.72 Anion 1.50  2.42 0.14 0.910 3.59 0.04 3.01 1.3829 0.0000 2.2184 
44 8-Phenyloctanoic acid 5.03 Anion  0.67 4.09 2.12 0.940 3.87 0.07 3.26 1.8965 0.0000 2.4256 
45 Salicylic acid 2.97 Anion 0.93  2.26 -1.77 1.050 3.51 0.14 2.18 0.9689 0.0000 1.6351 
46 Warfarin 4.98 Anion 1.57 0.35 2.70 0.68 2.130 5.62 0.00 4.40 2.2862 0.0000 2.7628 
 Basic compounds              
47 Acebutolol 9.52 Cation -0.02 0.14 2.02 -0.50 1.450 6.69 3.62 0.00 2.7771 2.2965 0.0000 
48 Alprenolol 9.59 Cation 0.31 0.71 3.10 0.51 1.100 4.46 1.78 0.00 2.1802 2.2574 0.0000 
49 Atenolol 9.60 Cation -0.19 0.06 0.16 -2.44 1.300 6.27 2.91 0.00 2.1978 2.4800 0.0000 
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50 Bupivacaine 8.10 Cation 0.36 0.64 3.41 2.28 1.170 4.67 2.92 0.00 2.5354 1.5920 0.0000 
51 Imipramine 9.40 Cation 0.83 1.18 4.80 2.40 1.000 3.66 2.02 0.00 2.4230 1.6110 0.0000 
52 Lidocaine 8.01 Cation 0.06 0.26 2.44 1.39 0.960 4.18 2.12 0.00 2.0804 1.7490 0.0000 
53 Mepivacaine 7.70 Cation -0.05 0.23 1.95 1.17 1.170 4.69 2.98 0.00 2.1127 1.5607 0.0000 
54 Metoprolol 9.63 Cation -0.02 0.12 1.95 -0.68 1.020 5.35 2.16 0.00 2.2819 2.3476 0.0000 
55 Oxprenolol 9.57 Cation 0.08 0.50 2.51 -0.06 1.160 5.09 2.35 0.00 2.2389 2.2029 0.0000 
56 Penbutolol 9.92 Cation 0.81 1.35 4.62 1.70 0.775 4.66 1.98 0.00 2.6195 1.9630 0.0000 
57 Pindolol 9.54 Cation 0.21 0.43 1.75 -0.79 1.550 4.60 2.36 0.00 2.0305 2.2661 0.0000 
58 Procaine 9.03 Cation 0.01 0.25 2.14 0.11 0.999 4.58 1.86 0.00 1.9982 2.1487 0.0000 
59 Promazine 9.36 Cation 1.01 1.34 4.55 2.19 1.900 3.78 1.76 0.00 2.3047 2.5263 0.0000 
60 Propafenone 9.62 Cation 0.65 1.09 3.64 1.02 1.680 5.69 3.08 0.00 2.8467 2.3780 0.0000 
61 Propranolol 9.47 Cation 0.54 0.98 3.48 1.01 1.690 4.31 2.07 0.00 2.1695 2.4319 0.0000 
62 Quinidine 8.56 Cation 0.47 0.77 3.44 1.87 2.320 5.81 1.23 0.00 2.5727 4.1570 0.0000 
63 Quinine 9.05 Cation 0.50 0.89 3.44 1.39 2.319 5.81 1.23 0.00 2.5727 4.1565 0.0000 
64 Sotalol 9.43 Cation -0.12 0.11 0.24 -2.19 1.320 6.18 2.38 0.00 2.1225 2.8119 0.0000 
65 Verapamil 8.92 Cation 0.57 0.77 3.79 1.86 1.660 7.70 4.33 0.00 3.8076 2.4040 0.0000 
a Taken from [21] and bioloom Software (Biobyte Corporation, Claremont, U.S.A.). 
b Calculated from Eq. 1; n=3, s.d. ≤ 0.03  
c Calculated according to for bases and  for acids. 
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Table 2. The observed log k values of ionic species and predicted log k values of the neutral species 
of acids and bases in this study by Eq 3 and Eq 4. 
Species E S A B V J+ J- logkHSAa logkAGPb 
Acids 
       
  
Aspirin, anion        0.86  
Aspirin 0.781 1.69 0.71 0.67 1.2879 0.0000 0.0000 -0.02  
4-Bromobenzoic Acid, anion        1.33  
4-Bromobenzoic Acid 1.000 1.01 0.63 0.26 1.1067 0.0000 0.0000 0.63  
3-Chlorobenzoic Acid, anion        1.04  
3-Chlorobenzoic Acid 0.840 0.95 0.63 0.32 1.0541 0.0000 0.0000 0.45  
4-Chlorobenzoic acid, anion        1.07  
4-Chlorobenzoic acid 0.840 1.02 0.63 0.27 1.0541 0.0000 0.0000 0.49  
Flurbiprofen, anion         0.14 
Flurbiprofen 1.440 1.45 0.62 0.76 1.8389 0.0000 0.0000  0.65 
Ibuprofen, anion         0.04 
Ibuprofen 0.730 0.70 0.57 0.79 1.7771 0.0000 0.0000  0.50 
Mefenamic acid, anion         0.63 
Mefenamic acid 1.650 1.35 0.65 0.54 1.9211 0.0000 0.0000  1.15 
3-Phenylpropanoic acid, anion        1.08  
3-Phenylpropanoic acid 0.750 1.18 0.60 0.60 1.2135 0.0000 0.0000 0.16  
4-Phenylbutanoic acid, anion        1.50  
4-Phenylbutanoic acid 0.760 1.29 0.61 0.57 1.3544 0.0000 0.0000 0.32  
8-Phenyloctanoic acid, anion         0.67 
8-Phenyloctanoic acid 0.790 1.28 0.59 0.63 1.9180 0.0000 0.0000  0.70 
Salicylic acid, anion        0.93  
Salicylic acid 0.900 0.85 0.73 0.37 0.9904 0.0000 0.0000 0.36  
Warfarin, anion        1.57 0.35 
Warfarin 1.980 1.88 0.29 1.57 2.3077 0.0000 0.0000 0.56 0.36 
Bases 
         
Acebutolol, cation        -0.02 0.14 
Acebutolol 1.600 2.42 0.90 2.10 2.7556 0.0000 0.0000 -0.08 -0.18 
Alprenolol, cation        0.31 0.71 
Alprenolol 1.250 1.09 0.15 1.44 2.1587 0.0000 0.0000 0.50 0.32 
Atenolol, cation        -0.19 0.06 
Atenolol 1.450 1.90 0.62 2.03 2.1763 0.0000 0.0000 -0.47 -0.67 
Bupivacaine, cation        0.36 0.64 
Bupivacaine 1.320 2.10 0.34 1.33 2.5139 0.0000 0.0000 0.68 0.56 
Imipramine, cation        0.89 1.08 
Imipramine 1.150 1.45 0.00 1.04 2.4015 0.0000 0.0000 1.12 0.99 
Lidocaine, cation        0.06 0.26 
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Lidocaine 1.110 1.51 0.07 1.24 2.0589 0.0000 0.0000 0.45 0.25 
Mepivacaine, cation        -0.05 0.23 
Mepivacaine 1.320 2.14 0.34 1.33 2.0912 0.0000 0.0000 0.21 0.00 
Metoprolol, cation        -0.02 0.12 
Metoprolol 1.170 1.33 0.17 1.76 2.2604 0.0000 0.0000 0.09 -0.07 
Oxprenolol, cation        0.08 0.50 
Oxprenolol 1.230 1.45 0.15 1.62 2.2174 0.0000 0.0000 0.21 0.04 
Penbutolol, cation        0.81 1.35 
Penbutolol 0.925 1.15 0.08 1.51 2.5980 0.0000 0.0000 0.73 0.65 
Pindolol, cation        0.21 0.43 
Pindolol 1.700 1.59 0.30 1.40 2.0090 0.0000 0.0000 0.40 0.18 
Procaine, cation        0.01 0.25 
Procaine 1.149 1.34 0.26 1.44 1.9767 0.0000 0.0000 0.15 -0.06 
Promazine, cation        1.01 1.34 
Promazine 2.050 1.49 0.00 1.08 2.2832 0.0000 0.0000 1.35 1.16 
Propafenone, cation        0.65 1.09 
Propafenone 1.730 2.09 0.29 1.74 2.8252 0.0000 0.0000 0.72 0.63 
Propranolol, cation        0.54 0.98 
Propranolol 1.840 1.43 0.44 1.31 2.1480 0.0000 0.0000 0.76 0.56 
Quinidine, cation        0.47 0.77 
Quinidine 2.469 1.23 0.37 1.97 2.5512 0.0000 0.0000 0.76 0.60 
Quinine, cation        0.50 0.89 
Quinine 2.469 1.23 0.37 1.97 2.5512 0.0000 0.0000 0.76 0.60 
Sotalol, cation        -0.12 0.11 
Sotalol 1.470 1.55 0.68 2.06 2.1010 0.0000 0.0000 -0.47 -0.68 
Verapamil, cation        0.57 0.77 
Verapamil 1.807 3.17 0.00 2.37 3.7861 0.0000 0.0000 0.72 0.76 
a Observed log kHSA values for ionic species and predicted log kHSA values for neutral species by Eq 3 
b Observed log kAGP values for ionic species and predicted log kAGP values for neutral species by Eq 4 
 
 
 
